Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674109 | 0.74 | HSP90AA1 (0.59) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL8120184 | 0.74 | KMT2A (0.50) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL297246 | 0.74 | HSP90AA1 (0.50) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL7048071 | 0.74 | HSP90AA1 (0.50) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5847774 | 0.72 | HSP90AA1 (0.53) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL713375 | 0.72 | HSP90AA1 (0.53) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5327423 | 0.71 | LMNA (0.53) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL8599037 | 0.69 | KMT2A (0.46) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL8432632 | 0.69 | HSP90AA1 (0.54) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL13965280 | 0.69 | KMT2A (0.55) | HSP90AA1ACHEKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | claimed |
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | SPONDULI SERVICES, LTD. (AU) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064954-A1 | Cationic amphiphilic 1,4-dihydropyridine derivatives useful for delivery of nucleotide containing compounds | ACIN1, DNA2, KPNA1 | HSP90AA1 2228/4885ACHE 3588/4885KMT2A 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.